{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T14:36:12Z","timestamp":1792506972944,"version":"4.5.0"},"reference-count":26,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T00:00:00Z","timestamp":1742169600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["dom-pubs.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Obesity Metabolism"],"published-print":{"date-parts":[[2025,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>To assess the efficacy and safety of switching from premixed insulin to a once\u2010daily, fixed\u2010ratio combination of insulin glargine 100\u2009U\/mL\u2009+\u2009lixisenatide (iGlarLixi) in people with type 2 diabetes (T2D).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this phase 4, 24\u2010week, single\u2010arm study, participants switched from once\u2010daily or twice\u2010daily premixed insulin to iGlarLixi (EudraCT number 2021\u2013003711\u201025). Key inclusion criteria: \u226518\u2009years; premixed insulin therapy for \u22653\u2009months and\u2009&lt;\u200910\u2009years; \u00b1\u20091\u20132 oral antidiabetic drugs (OADs); HbA1c \u22657.5% to \u226410.0%. The primary endpoint was the change in HbA1c from baseline to Week 24. Secondary endpoints included: participants achieving HbA1c &lt;7% and change in body weight at Week 24, and safety.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Overall, 162 participants switched to iGlarLixi (89.5% from twice\u2010daily premixed insulin); mean duration of diabetes was 15.7 (standard deviation [SD]: 8.3) years. Mean baseline HbA1c (8.5%) reduced by least squares (LS) mean of 1.2% (95% confidence interval [CI]: \u22121.4, \u22121.1) at Week 24, and 37.6% of participants had achieved an HbA1c target of &lt;7% (95% CI: 30.0, 45.7). LS mean body weight change from baseline to Week 24 was \u22121.0\u2009kg (95% CI: \u22121.6, \u22120.5). Fasting and post\u2010prandial plasma glucose decreased from baseline to Week 24 by 45.6\u2009mg\/dL (SD\u2009\u00b1\u200952.4) and 67.6\u2009mg\/dL (SD\u2009\u00b1\u200965.1), respectively. Confirmed symptomatic hypoglycaemia occurred in 38.3% of participants (ADA level 1: 35.8%; level 2: 15.4%; level 3: 0.0%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>iGlarLixi initiation was associated with improved glycaemic control, without body weight gain or increased hypoglycaemia over 24\u2009weeks.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/dom.16276","type":"journal-article","created":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T01:15:57Z","timestamp":1742260557000},"page":"2730-2739","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Efficacy and safety of switching to\n                    <scp>iGlarLixi<\/scp>\n                    from premixed insulins in people with type 2 diabetes: The Soli\u2010\n                    <scp>SWITCH<\/scp>\n                    study"],"prefix":"10.1111","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0201-6888","authenticated-orcid":false,"given":"Martin","family":"Haluz\u00edk","sequence":"first","affiliation":[{"name":"Diabetes Centre, Institute for Clinical and Experimental Medicine (IKEM)  Prague Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarzyna","family":"Cypryk","sequence":"additional","affiliation":[{"name":"Department of Internal Diseases and Diabetology Medical University of Lodz  Lodz Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agustina","family":"Alvarez","sequence":"additional","affiliation":[{"name":"Sanofi  Madrid Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felipe","family":"Lauand","sequence":"additional","affiliation":[{"name":"Sanofi  Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9rie","family":"Corp dit Genti","sequence":"additional","affiliation":[{"name":"Sanofi  Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Okan Sefa","family":"Bakiner","sequence":"additional","affiliation":[{"name":"Adana Dr. Turgut Noyan Training and Research Hospital, Endocrinology Baskent University  Adana Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4137-1671","authenticated-orcid":false,"given":"Soo","family":"Lim","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine Seoul National University College of Medicine and Seoul National University Bundang Hospital  Seongnam Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,3,17]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2013.0081"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc24-S009"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-022-05787-2"},{"key":"e_1_2_10_5_1","unstructured":"European Medicines Agency.European Medicines Agency. Suliqua: EPAR\u2010Product information.2023https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/suliqua-epar-product-information_en.pdfAccessed November 7 2024."},{"key":"e_1_2_10_6_1","unstructured":"Food and Drug Adminstration.Soliqua prescribing information.2019https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/208673s007lbl.pdfAccessed November 7 2024."},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1177\/1932296819891170"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc16-0917"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc16-1495"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc19-1357"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc21-0393"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14822"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.15724"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2007.07.003"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc08-2117"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc10-1701"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa075392"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.2337\/dci18-0033"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2018.0132"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc17-1624"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc21-S006"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14844"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-019-00730-y"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.15857"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13098-020-00559-7"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12290"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.regpep.2013.04.001"}],"container-title":["Diabetes, Obesity and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/pdf\/10.1111\/dom.16276","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T22:55:59Z","timestamp":1761864959000},"score":1,"resource":{"primary":{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/10.1111\/dom.16276"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,17]]},"references-count":26,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["10.1111\/dom.16276"],"URL":"https:\/\/doi.org\/10.1111\/dom.16276","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.1111\/DOM.16276\/v2\/response1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.16276\/v2\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.16276\/v1\/review4","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.16276\/v1\/review3","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.16276\/v1\/review2","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.16276\/v1\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.16276\/v1\/review1","asserted-by":"object"}]},"ISSN":["1462-8902","1463-1326"],"issn-type":[{"value":"1462-8902","type":"print"},{"value":"1463-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,17]]},"assertion":[{"value":"2024-11-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-02-05","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-03-17","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}